0001140361-22-028093.txt : 20220803 0001140361-22-028093.hdr.sgml : 20220803 20220803200121 ACCESSION NUMBER: 0001140361-22-028093 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220801 FILED AS OF DATE: 20220803 DATE AS OF CHANGE: 20220803 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Singer Nicholas Jason CENTRAL INDEX KEY: 0001828224 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11460 FILM NUMBER: 221134197 MAIL ADDRESS: STREET 1: 1395 BRICKELL AVENUE STREET 2: SUITE 800 CITY: MIAMI STATE: FL ZIP: 33131 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc. CENTRAL INDEX KEY: 0000748592 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 311103425 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 140 58TH STREET, BUILDING A STREET 2: SUITE 2100 CITY: BROOKLYN STATE: NY ZIP: 11220 BUSINESS PHONE: (212) 582-1199 MAIL ADDRESS: STREET 1: 140 58TH STREET, BUILDING A STREET 2: SUITE 2100 CITY: BROOKLYN STATE: NY ZIP: 11220 FORMER COMPANY: FORMER CONFORMED NAME: NTN BUZZTIME INC DATE OF NAME CHANGE: 20051230 FORMER COMPANY: FORMER CONFORMED NAME: NTN COMMUNICATIONS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ALROY INDUSTRIES INC DATE OF NAME CHANGE: 19850411 4 1 form4.xml FORM 4 X0306 4 2022-08-01 0000748592 Brooklyn ImmunoTherapeutics, Inc. BTX 0001828224 Singer Nicholas Jason C/O BROOKLYN IMMUNOTHERAPEUTICS, INC. 10355 SCIENCE CENTER DRIVE, SUITE 150 SAN DIEGO CA 92121 true Stock Option (right to buy) 0.49 2022-08-01 4 A 0 146100 0 A 2032-08-01 Common Stock, par value $0.005 per share 146100 146100 D Stock Option (right to buy) 0.49 2022-08-01 4 A 0 165800 0 A 2032-08-01 Common Stock, par value $0.005 per share 165800 165800 D The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date. The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter. /s/ Nicholas J. Singer 2022-08-03